News

MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient. The Company plans to enroll 12 patients

The phase 3 CheckMate -498 trial assessing Opdivo plus radiation against temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM) did not achieve

Under the terms of the agreement, Pfizer will acquire Therachon for $340m upfront with an additional $470m in additional payments contingent on the achievement of key milestones in

As per terms of the agreement, Takeda is also eligible to secure up to an additional $1.9bn in potential milestone payments from Novartis along with $3.4bn upfront payment

It is the company’s investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age. In

“Pfizer has worked to pioneer biomarker-driven medicine for patients with ALK-positive non-small cell lung cancer and we continue to advance patient care with the approval of LORVIQUA,” said

This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer’s disease dementia, and in the trial, BELSOMRA met its primary

Through the early-stage trial called DUET-3, Xencor will assess the safety and tolerability of XmAb23104 in an estimated 144 patients with selected advanced solid tumors. The participants will

The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant treatment with taxane and Herceptin (trastuzumab). The